188 related articles for article (PubMed ID: 18855101)
1. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature.
Yokoyama H; Watanabe T; Maruyama D; Kim SW; Kobayashi Y; Tobinai K
Int J Hematol; 2008 Nov; 88(4):443-447. PubMed ID: 18855101
[TBL] [Abstract][Full Text] [Related]
2. Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review.
Felli V; Di Sibio A; Anselmi M; Gennarelli A; Sucapane P; Splendiani A; Catalucci A; Marini C; Gallucci M
Neuroradiol J; 2014 Dec; 27(6):657-64. PubMed ID: 25489887
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphoma.
Sikkema T; Schuiling WJ; Hoogendoorn M
BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23355583
[TBL] [Abstract][Full Text] [Related]
4. A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?
Tadmor T; McLaughlin P; Polliack A
Leuk Lymphoma; 2010 May; 51(5):737-8. PubMed ID: 20367567
[No Abstract] [Full Text] [Related]
5. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
[No Abstract] [Full Text] [Related]
6. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
7. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
[TBL] [Abstract][Full Text] [Related]
8. The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience.
Hardak E; Oren I; Dann EJ; Yigla M; Faibish T; Rowe JM; Avivi I
Acta Haematol; 2012; 127(2):110-4. PubMed ID: 22178955
[TBL] [Abstract][Full Text] [Related]
9. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
[TBL] [Abstract][Full Text] [Related]
10. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone.
Kamel S; O'Connor S; Lee N; Filshie R; Nandurkar H; Tam CS
Leuk Lymphoma; 2010 May; 51(5):797-801. PubMed ID: 20367135
[TBL] [Abstract][Full Text] [Related]
11. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
12. Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy.
Kim T; Choi SH; Kim SH; Jeong JY; Woo JH; Kim YS; Sung H; Kim MN; Yoon DH; Suh C; Lee SO
Ann Hematol; 2013 Jan; 92(2):231-8. PubMed ID: 23053189
[TBL] [Abstract][Full Text] [Related]
13. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
14. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F; Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F; Baccarani M; Zinzani PL
Leuk Lymphoma; 2009 Nov; 50(11):1824-9. PubMed ID: 19814687
[TBL] [Abstract][Full Text] [Related]
16. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.
Halaas JL; Moskowitz CH; Horwitz S; Portlock C; Noy A; Straus D; O'Connor OA; Yahalom J; Zelenetz AD
Leuk Lymphoma; 2005 Apr; 46(4):541-7. PubMed ID: 16019482
[TBL] [Abstract][Full Text] [Related]
17. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
Kayamori K; Shono K; Onoda M; Yokota A
Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
20. Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?
Lee GW; Kang JH; Kim IS; Kim HG; Ko GH; Lee JH; Kim DC; Song DH; Yang JW; Lee JS
Leuk Lymphoma; 2009 Dec; 50(12):1992-8. PubMed ID: 19860620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
